The year in cardiothoracic and vascular anesthesia: Selected highlights from 2011

Prakash A. Patel, Harish Ramakrishna, Michael Andritsos, Tygh Wyckoff, Hynek Riha, John G T Augoustides

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

There have been rapid advances in oral anticoagulation. The oral factor Xa inhibitors rivaroxaban and apixaban and the oral direct thrombin inhibitor dabigatran recently have been rigorously evaluated. These novel anticoagulants will usher in a new paradigm for perioperative anticoagulation. Perioperative blood conservation in cardiac surgery recently has been highlighted in the updated guidelines by the Society of Cardiovascular Anesthesiologists and the Society of Thoracic Surgeons. These recommendations reflect a comprehensive evaluation of the recent evidence to optimize transfusion practice. Transcatheter mitral valve repair continues to mature. Transcatheter aortic valve implantation for aortic stenosis has entered the clinical mainstream, with randomized trials showing its superiority over medical management and its equivalency to surgical valve replacement in high-risk patients. This transformational technology represents a major leadership opportunity for the cardiac anesthesiologist. Minimally invasive valve surgery has shown effectiveness in high-risk patients. Radial access is equivalent to femoral access for percutaneous coronary intervention in acute coronary syndromes but significantly reduces the risk of local vascular complications. Recent trials have further clarified the roles of medical therapy, percutaneous coronary intervention, and coronary artery bypass surgery in patients with significant coronary artery disease and left ventricular dysfunction. The past year has witnessed major advances in cardiovascular practice with new drugs, new devices, and new guidelines. The coming year most likely will advance these achievements to enhance the care of patients.

Original languageEnglish (US)
Pages (from-to)3-10
Number of pages8
JournalJournal of Cardiothoracic and Vascular Anesthesia
Volume26
Issue number1
DOIs
StatePublished - Feb 2012

Fingerprint

Blood Vessels
Anesthesia
Percutaneous Coronary Intervention
Guidelines
Minimally Invasive Surgical Procedures
Antithrombins
Aortic Valve Stenosis
Left Ventricular Dysfunction
Acute Coronary Syndrome
Thigh
Mitral Valve
Surgical Instruments
Coronary Artery Bypass
Anticoagulants
Thoracic Surgery
Coronary Artery Disease
Patient Care
Technology
Equipment and Supplies
Pharmaceutical Preparations

Keywords

  • aminocaproic acid
  • antifibrinolytics
  • apixaban
  • blood conservation guidelines
  • blood salvage
  • cardiopulmonary bypass
  • clopidogrel
  • coronary artery bypass surgery
  • dabigatran
  • direct thrombin inhibitor
  • erythropoietin
  • factor concentrates
  • factor Xa inhibitor
  • femoral artery
  • fresh frozen plasma
  • heart failure
  • leukoreduction
  • microplegia
  • minimally invasive surgery
  • percutaneous coronary intervention
  • platelet blockade
  • point-of-care testing
  • radial artery
  • rivaroxaban
  • thoracic endovascular repair
  • tranexamic acid
  • transcatheter aortic valve implantation
  • transcatheter mitral valve repair
  • ultrafiltration

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Anesthesiology and Pain Medicine

Cite this

The year in cardiothoracic and vascular anesthesia : Selected highlights from 2011. / Patel, Prakash A.; Ramakrishna, Harish; Andritsos, Michael; Wyckoff, Tygh; Riha, Hynek; Augoustides, John G T.

In: Journal of Cardiothoracic and Vascular Anesthesia, Vol. 26, No. 1, 02.2012, p. 3-10.

Research output: Contribution to journalArticle

Patel, Prakash A. ; Ramakrishna, Harish ; Andritsos, Michael ; Wyckoff, Tygh ; Riha, Hynek ; Augoustides, John G T. / The year in cardiothoracic and vascular anesthesia : Selected highlights from 2011. In: Journal of Cardiothoracic and Vascular Anesthesia. 2012 ; Vol. 26, No. 1. pp. 3-10.
@article{24a3a0f79e434ae68bd956393b88331a,
title = "The year in cardiothoracic and vascular anesthesia: Selected highlights from 2011",
abstract = "There have been rapid advances in oral anticoagulation. The oral factor Xa inhibitors rivaroxaban and apixaban and the oral direct thrombin inhibitor dabigatran recently have been rigorously evaluated. These novel anticoagulants will usher in a new paradigm for perioperative anticoagulation. Perioperative blood conservation in cardiac surgery recently has been highlighted in the updated guidelines by the Society of Cardiovascular Anesthesiologists and the Society of Thoracic Surgeons. These recommendations reflect a comprehensive evaluation of the recent evidence to optimize transfusion practice. Transcatheter mitral valve repair continues to mature. Transcatheter aortic valve implantation for aortic stenosis has entered the clinical mainstream, with randomized trials showing its superiority over medical management and its equivalency to surgical valve replacement in high-risk patients. This transformational technology represents a major leadership opportunity for the cardiac anesthesiologist. Minimally invasive valve surgery has shown effectiveness in high-risk patients. Radial access is equivalent to femoral access for percutaneous coronary intervention in acute coronary syndromes but significantly reduces the risk of local vascular complications. Recent trials have further clarified the roles of medical therapy, percutaneous coronary intervention, and coronary artery bypass surgery in patients with significant coronary artery disease and left ventricular dysfunction. The past year has witnessed major advances in cardiovascular practice with new drugs, new devices, and new guidelines. The coming year most likely will advance these achievements to enhance the care of patients.",
keywords = "aminocaproic acid, antifibrinolytics, apixaban, blood conservation guidelines, blood salvage, cardiopulmonary bypass, clopidogrel, coronary artery bypass surgery, dabigatran, direct thrombin inhibitor, erythropoietin, factor concentrates, factor Xa inhibitor, femoral artery, fresh frozen plasma, heart failure, leukoreduction, microplegia, minimally invasive surgery, percutaneous coronary intervention, platelet blockade, point-of-care testing, radial artery, rivaroxaban, thoracic endovascular repair, tranexamic acid, transcatheter aortic valve implantation, transcatheter mitral valve repair, ultrafiltration",
author = "Patel, {Prakash A.} and Harish Ramakrishna and Michael Andritsos and Tygh Wyckoff and Hynek Riha and Augoustides, {John G T}",
year = "2012",
month = "2",
doi = "10.1053/j.jvca.2011.10.005",
language = "English (US)",
volume = "26",
pages = "3--10",
journal = "Journal of Cardiothoracic and Vascular Anesthesia",
issn = "1053-0770",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - The year in cardiothoracic and vascular anesthesia

T2 - Selected highlights from 2011

AU - Patel, Prakash A.

AU - Ramakrishna, Harish

AU - Andritsos, Michael

AU - Wyckoff, Tygh

AU - Riha, Hynek

AU - Augoustides, John G T

PY - 2012/2

Y1 - 2012/2

N2 - There have been rapid advances in oral anticoagulation. The oral factor Xa inhibitors rivaroxaban and apixaban and the oral direct thrombin inhibitor dabigatran recently have been rigorously evaluated. These novel anticoagulants will usher in a new paradigm for perioperative anticoagulation. Perioperative blood conservation in cardiac surgery recently has been highlighted in the updated guidelines by the Society of Cardiovascular Anesthesiologists and the Society of Thoracic Surgeons. These recommendations reflect a comprehensive evaluation of the recent evidence to optimize transfusion practice. Transcatheter mitral valve repair continues to mature. Transcatheter aortic valve implantation for aortic stenosis has entered the clinical mainstream, with randomized trials showing its superiority over medical management and its equivalency to surgical valve replacement in high-risk patients. This transformational technology represents a major leadership opportunity for the cardiac anesthesiologist. Minimally invasive valve surgery has shown effectiveness in high-risk patients. Radial access is equivalent to femoral access for percutaneous coronary intervention in acute coronary syndromes but significantly reduces the risk of local vascular complications. Recent trials have further clarified the roles of medical therapy, percutaneous coronary intervention, and coronary artery bypass surgery in patients with significant coronary artery disease and left ventricular dysfunction. The past year has witnessed major advances in cardiovascular practice with new drugs, new devices, and new guidelines. The coming year most likely will advance these achievements to enhance the care of patients.

AB - There have been rapid advances in oral anticoagulation. The oral factor Xa inhibitors rivaroxaban and apixaban and the oral direct thrombin inhibitor dabigatran recently have been rigorously evaluated. These novel anticoagulants will usher in a new paradigm for perioperative anticoagulation. Perioperative blood conservation in cardiac surgery recently has been highlighted in the updated guidelines by the Society of Cardiovascular Anesthesiologists and the Society of Thoracic Surgeons. These recommendations reflect a comprehensive evaluation of the recent evidence to optimize transfusion practice. Transcatheter mitral valve repair continues to mature. Transcatheter aortic valve implantation for aortic stenosis has entered the clinical mainstream, with randomized trials showing its superiority over medical management and its equivalency to surgical valve replacement in high-risk patients. This transformational technology represents a major leadership opportunity for the cardiac anesthesiologist. Minimally invasive valve surgery has shown effectiveness in high-risk patients. Radial access is equivalent to femoral access for percutaneous coronary intervention in acute coronary syndromes but significantly reduces the risk of local vascular complications. Recent trials have further clarified the roles of medical therapy, percutaneous coronary intervention, and coronary artery bypass surgery in patients with significant coronary artery disease and left ventricular dysfunction. The past year has witnessed major advances in cardiovascular practice with new drugs, new devices, and new guidelines. The coming year most likely will advance these achievements to enhance the care of patients.

KW - aminocaproic acid

KW - antifibrinolytics

KW - apixaban

KW - blood conservation guidelines

KW - blood salvage

KW - cardiopulmonary bypass

KW - clopidogrel

KW - coronary artery bypass surgery

KW - dabigatran

KW - direct thrombin inhibitor

KW - erythropoietin

KW - factor concentrates

KW - factor Xa inhibitor

KW - femoral artery

KW - fresh frozen plasma

KW - heart failure

KW - leukoreduction

KW - microplegia

KW - minimally invasive surgery

KW - percutaneous coronary intervention

KW - platelet blockade

KW - point-of-care testing

KW - radial artery

KW - rivaroxaban

KW - thoracic endovascular repair

KW - tranexamic acid

KW - transcatheter aortic valve implantation

KW - transcatheter mitral valve repair

KW - ultrafiltration

UR - http://www.scopus.com/inward/record.url?scp=84855326101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855326101&partnerID=8YFLogxK

U2 - 10.1053/j.jvca.2011.10.005

DO - 10.1053/j.jvca.2011.10.005

M3 - Article

C2 - 22221506

AN - SCOPUS:84855326101

VL - 26

SP - 3

EP - 10

JO - Journal of Cardiothoracic and Vascular Anesthesia

JF - Journal of Cardiothoracic and Vascular Anesthesia

SN - 1053-0770

IS - 1

ER -